ESC 365 - Percutaneous left atrial appendage closure versus novel anticoagulation agents in high-risk atrial fibrillation patients (PRAGUE-17 study)

ESC Premium Access

Percutaneous left atrial appendage closure versus novel anticoagulation agents in high-risk atrial fibrillation patients (PRAGUE-17 study)

Session: Late Breaking Science in Intervention

Topic: Stroke in Atrial Fibrillation

Speaker: Doctor P. Osmancik (Prague, CZ)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Pavel Osmancik

Charles University of Prague, Prague (Czechia)

1 presentation

0 follower

4 more presentations in this session

Immediate versus Delayed Stenting After Primary Percutaneous Reperfusion in ST-Elevation Myocardial Infarction: The PRIMACY Bayesian Randomized Controlled Trial

Speaker: Doctor M. Jolicoeur (Montreal, CA)

Ultrathin-strut biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in acute myocardial infarction: a randomized controlled trial

Speaker: Doctor J. Iglesias (Geneva, CH)

Low-dose rivaroxaban after left atrial appendage closure: The randomized ADRIFT study

Speaker: Professor G. Montalescot (Paris, FR)

Randomized, Multicenter Comparison of Intensified versus Standard Loading Strategies with P2Y12-Receptor-Inhibitors in Patients Undergoing Elective PCI

Speaker: Professor J. Mehilli (Landshut, DE)

Access the full session

Late Breaking Science in Intervention

Speakers: Doctor P. Osmancik, Doctor M. Jolicoeur, Doctor J. Iglesias, Professor G. Montalescot, Professor J. Mehilli

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources